Poster Sessions—Monday, September 24, 2018P1.13-06 First-Line Lorlatinib Versus Crizotinib for Advanced Anaplastic Lymphoma Kinase-Positive (ALK+) Non-Small Cell Lung Cancer
Under an Elsevier user license
open archive
Cited by (0)
Copyright © 2018 Published by Elsevier Inc.